BeyondSpring (BYSI) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for BeyondSpring
Is BeyondSpring a buy right now? The alternative data says hold. This BYSI stock analysis is built on the 25+ alternative data signals AltIndex tracks on BeyondSpring every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 42/100: a Hold. The stock trades at $0.79 with a $32M market cap.
The soft spots over the past 90 days: web traffic down 8.0% to 2K monthly visits, just 37% of employees report a positive business outlook, and sentiment down 6.0% to 94/100. The rest of the signal set is holding steady, which keeps BYSI at a hold rather than a sell.
BYSI’s broader alt-data profile also covers headcount (54 employees, according to LinkedIn). Every signal links to its own page with full history, the BYSI technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on BYSI is just below.
BeyondSpring AI Stock Analysis
BeyondSpring Inc. is a global biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company's leading product candidate, Plinabulin, is in late-stage clinical trials for the prevention of chemotherapy-induced neutropenia (CIN) and as a combination therapy in non-small cell lung cancer (NSCLC).
Analysis generated October 1, 2026.
Recent BeyondSpring Stock Alerts
|
BeyondSpring | October 5 Price is down by -6.1% in the last 24h. |
|
BeyondSpring | October 1 Price is up by 9.6% in the last 24h. |
|
BeyondSpring | September 30 Price is down by -6.4% in the last 24h. |
|
BeyondSpring | September 29 Price is down by -26.8% in the last 24h. |
BeyondSpring Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 8.0% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 54 | 3.8% | |
| Employee Recommend | 33 | 0% | |
| Business Outlook | 37 | 0% | |
| Sentiment | 94 | 6.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 74 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 5K | 0.6% |
About BeyondSpring (BYSI)
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
| Price | $0.79 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $32M |
| Year Range | $1 – $2 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest BeyondSpring News
View more → |
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14 - Associated Press |
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual MeetingMay 18 - GlobeNewswire |
|
 |
ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsightJuly 23 - PRNewswire |
Dysmenorrhea Treatment Market Size to Hit USD 12.70 Billion by 2035, Growing at 7.68% CAGR | SNS InsiderJuly 22 - GlobeNewswire |
|
 |
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsightJuly 2 - PRNewswire |
See BeyondSpring’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for BYSI, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEBeyondSpring Earnings & Financial Performance
View all earnings →BeyondSpring Insider Trading Activity
View all →| Cui Xiangmin filed to sell 1,518,893 shares at $0.0. Oct 17 '25 |
| Cui Xiangmin filed to sell 1,564,406 shares at $0.0. Oct 16 '25 |
| Cui Xiangmin filed to sell 1,650,204 shares at $0.0. Oct 15 '25 |
| Cui Xiangmin filed to sell 1,668,164 shares at $0.0. Oct 14 '25 |
| Cui Xiangmin filed to sell 1,696,659 shares at $0.0. Oct 13 '25 |
BeyondSpring Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to BeyondSpring
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
NanoViricidesNNVC |
$1.45 13.3% | $33M | 52 |
 |
ImmutepIMMP |
$4.27 1.8% | $32M | 50 |
 |
China Pharma HoldingCPHI |
$0.65 0.6% | $28M | 50 |
 |
aTyr PharmaATYR |
$0.29 1.0% | $28M | 53 |
 |
Actinium PharmaceuticalsATNM |
$1.20 2.6% | $37M | 47 |
Explore BeyondSpring Data
Frequently Asked Questions: BeyondSpring (BYSI)
BeyondSpring has an AltIndex AI Score of 42/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
42/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of BeyondSpring (BYSI) stock is $0.79 with a market cap of $32M.
As of today, BeyondSpring’s PE (Price to Earnings) ratio is —.
View the latest BeyondSpring insider transactions to see recent buying and selling activity by company executives and directors.
Check the BeyondSpring congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The BYSI stock price chart above shows BeyondSpring’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full BeyondSpring technical analysis for RSI, moving averages, and more.
See the stocks similar to BeyondSpring section on this page for companies in the same industry ranked by market cap and AI Score.
